A decision reached by Trimeris Inc. and F. Hoffmann-La Roche Ltd. to halt clinical development of the early-stage HIV candidate T-1249 did not trigger a stock slide of devastating proportions for Trimeris, the company that discovered Fuzeon, a first-in-class fusion inhibitor for HIV patients. (BioWorld Today) Read More
